Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related SPKE
Mid-Morning Market Update: Markets Mostly Flat; Citigroup Earnings Beat Expectations
Mid-Afternoon Market Update: NASDAQ Slides Over 2.5%; Micro Focus Shares Plummet
Spark Energy, Inc. to Present First Quarter —…–8 Financial Results on Thursday, May ... (GuruFocus)
Related MDLY
Earnings Scheduled For March 29, 2018
Earnings Scheduled For May 12, 2017

 

  • Analysts at Ladenburg Thalmann initiated coverage on Spark Energy Inc (NASDAQ: SPKE) with a Neutral rating. The price target for Spark Energy is set to $27. Spark Energy shares gained 1.17 percent to close at $26.02 on Thursday.
  • Compass Point initiated coverage of Medley Management Inc (NYSE: MDLY) with a Buy rating. The price target for Medley Management is set to $9.25. Medley Management shares fell 1.95 percent to close at $7.54 on Thursday.
  • Analysts at BTIG Research initiated coverage on Acceleron Pharma Inc (NASDAQ: XLRN) with a Buy rating. The price target for Acceleron Pharma is set to $46. Acceleron Pharma shares fell 0.03 percent to close at $30.00 on Thursday.
  • Analysts at Benchmark initiated coverage of Tegna Inc (NYSE: TGNA) with a Buy rating. The price target for Tegna is set to $26. Tegna shares slipped 0.23 percent to close at $21.30 on Thursday.
  • Analysts at SunTrust Robinson Humphrey initiated coverage on Eldorado Resorts Inc (NASDAQ: ERI) with a Buy rating. Eldorado Resorts shares rose 3.02 percent to close at $14.00 on Thursday.
  • Analysts at Bernstein initiated coverage of Teck Resources Ltd (USA) (NYSE: TCK) with a Sell rating. The price target for Teck Resources is set to $10. Teck Resources shares dropped 2.91 percent to $16.02 in pre-market trading.
  • RBC Capital initiated coverage on American Midstream Partners LP (NYSE: AMID) with a Outperform rating. American Midstream shares rose 0.83 percent to close at $12.16 on Thursday.
  • Analysts at BTIG Research initiated coverage on Merrimack Pharmaceuticals Inc (NASDAQ: MACK) with a Neutral rating. Merrimack Pharmaceuticals shares gained 2.04 percent to close at $5.01 on Thursday.

Latest Ratings for SPKE

DateFirmActionFromTo
Nov 2017B. RileyDowngradesBuyNeutral
Nov 2017Janney CapitalUpgradesNeutralBuy
Jul 2017GuggenheimUpgradesNeutralBuy

View More Analyst Ratings for SPKE
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ERI + AMID)

View Comments and Join the Discussion!